Valuation: Acurx Pharmaceuticals, Inc.

Market Cap 5.98M 5.34M 4.93M 4.47M 8.37M 568M 8.5M 59.38M 23.51M 297M 22.45M 21.97M 938M P/E 2026 *
-0.69x
P/E 2027 * -0.87x
Enterprise Value 5.98M 5.34M 4.93M 4.47M 8.37M 568M 8.5M 59.38M 23.51M 297M 22.45M 21.97M 938M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.69%
Yield 2026 *
-
Yield 2027 * -
10-21 Acurx Pharmaceuticals, Inc. Announces Publication In ASM Confirming Data On Its DNA Pol IIIC Inhibitor Pipeline Of Antibiotics Demonstrating A Potential Microbiome-Sparing Class Effect CI
09-29 Acurx Pharmaceuticals, Inc. Enrolls First Patient In PATHFINDER Clinical Trial Of Ibezapolstat In Multiply-Recurrent C. Difficile Infection CI
08-17 Acurx Pharmaceuticals Receives FDA Conditional Acceptance And USPTO Trademark Allowance For CIFBEZY Brand Name For Ibezapolstat CI
08-14 Acurx Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 14, 2026
08-13 Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-12 Acurx Pharmaceuticals Secures New Patents for Dna Polymerase Iiic Inhibitor Antibiotics in Japan and Mexico CI
08-10 Acurx Pharmaceuticals, Inc. and Leiden University Medical Center Announce Scientific Partnership to Advance Development of Dna Polymerase IIIC Inhibitor Antibiotics CI
08-03 Acurx Pharmaceuticals Receives FDA Guidance For Ibezapolstat Clinical Development Program And Initiates IBZ-PATHFINDER Trial CI
07-14 Acurx Pharmaceuticals Presents Scientific Poster On Ibezapolstat Microbiome Preservation Data And Initiates Clinical Trial Activities For Multiply-Recurrent C. Difficile Infection CI
06-16 Acurx Pharmaceuticals, Inc. Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA Pol IIIC Inhibitors At The Leiden Early Drug Discovery & Development Scientific Conference CI
06-15 Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. CI
06-15 Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. CI
06-15 Certain Stock Options of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. CI
1 day-0.44%
1 week+3.18%
Current month-9.92%
1 month-16.54%
3 months-20.07%
6 months-42.68%
Current year-54.42%
1 week 1.1
Extreme 1.1
1.18
1 month 1.07
Extreme 1.0688
1.38
Current year 1.07
Extreme 1.0688
7.54
1 year 1.07
Extreme 1.0688
7.54
3 years 1.07
Extreme 1.0688
114
5 years 1.07
Extreme 1.0688
176.4
10 years 1.07
Extreme 1.0688
176.4
Manager TitleAgeSince
Director of Finance/CFO 59 2017-06-30
Chief Executive Officer 59 2017-06-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Chairman 80 2017-06-30
Director/Board Member 56 2018-10-22
Date Insider Type Main position Quantity % Market Cap. Importance
4/20/26 Free

Director

2,150 0.1357%
4/20/26 Free

Founder

37,100 2.3410%
4/20/26 Free

Director

2,150 0.1357%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+3.18%-82.57%-98.61% 5.98M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.20%+2.49%+35.01%+116.94% 38.31B
Weighted average by Cap. +0.39%+2.73%+46.02%+142.83%

Financials

2026 *2027 *
Net sales - -
Net income -8.74M -7.81M -7.21M -6.54M -12.23M -830M -12.43M -86.79M -34.36M -435M -32.81M -32.11M -1.37B -11.3M -10.09M -9.32M -8.45M -15.8M -1.07B -16.07M -112M -44.41M -562M -42.41M -41.51M -1.77B
Net Debt - -
Projected Income Statement - Annual - Acurx Pharmaceuticals, Inc.
Logo Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Employees
-
Date Price Change Volume
26-10-23 US$1.135 -0.44% 22,153
26-10-22 US$1.140 -0.87% 26,544
26-10-21 US$1.150 +0.88% 20,961
26-10-20 US$1.140 0.00% 68,303
26-10-19 US$1.140 +3.64% 51,098
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Acurx Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.135USD
Average target price
17.00USD
Spread / Average Target
+1,397.80%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Acurx Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ACXP Stock